Literature DB >> 10906742

Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells.

A Kumar1, S D Mikolajczyk, T M Hill, L S Millar, M S Saedi.   

Abstract

BACKGROUND: Human prostate-specific antigen (PSA) and human kallikrein 2 (hK2) are expressed primarily by prostate epithelial cells. PSA and hK2 both exist as free protein and complexed with protease inhibitors (e.g., alpha1-antichymotrypsin, ACT) in serum. The expression of PSA and hK2 in LNCaP cells is upregulated by androgen.
METHODS: LNCaP, a prostate cancer cell line that secretes both PSA and hK2, was used as a model to study the biosynthesis and processing of PSA and hK2 upon androgen induction.
RESULTS: Precursor (zymogen or pro) forms of both PSA and hK2 were detected in spent media of induced and noninduced LNCaP cells, indicating that PSA and hK2 are secreted as proPSA (pPSA) and prohK2 (phK2), respectively, and are converted to the mature forms extracellularly. A 3-fold higher ratio of mature to pPSA was detected in the spent media of mibolerone-induced LNCaP cells compared to noninduced cells. In addition to the inactive proform of PSA, more than half of the mature unclipped PSA present in the spent media did not complex with exogenously added ACT. Spent media of mibolerone-induced LNCaP cells contained nearly 100% mature hK2, whereas the spent media of noninduced cells contained mostly phK2.
CONCLUSIONS: These results indicate that androgens not only upregulate the expression of these kallikreins, but also have a significant effect on the processing of PSA and hK2. These results also show that LNCaP cells express a heterogeneous mixture of inactive PSA and hK2 forms that may serve as a model for the genesis of these forms in physiological fluids. These findings may also provide insights into the forms and ratios of PSA and hK2 in normal and malignant breast tissues. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906742     DOI: 10.1002/1097-0045(20000801)44:3<248::aid-pros10>3.0.co;2-d

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

1.  Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.

Authors:  Shahrokh F Shariat; Eduardo I Canto; Michael W Kattan; Kevin M Slawin
Journal:  Rev Urol       Date:  2004

2.  Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.

Authors:  Simon A Williams; Yi Xu; Angelo M De Marzo; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2010-05-15       Impact factor: 4.104

Review 3.  PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.

Authors:  Sema Nur Ayyıldız; Ali Ayyıldız
Journal:  Turk J Urol       Date:  2014-06

Review 4.  [Isoforms of free prostate-specific antigen].

Authors:  A Haese; J Noldus; T Steuber; H Huland; H Lilja
Journal:  Urologe A       Date:  2004-06       Impact factor: 0.639

Review 5.  Emerging PSA-based tests to improve screening.

Authors:  Richard J Bryant; Hans Lilja
Journal:  Urol Clin North Am       Date:  2014-02-26       Impact factor: 2.241

Review 6.  Molecular diagnosis of prostate cancer.

Authors:  Eduardo I Canto; Shahrokh F Shariat; Kevin M Slawin
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.